AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 86 filers reported holding AVADEL PHARMACEUTICALS PLC in Q4 2021. The put-call ratio across all filers is 0.52 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $226,085 | -32.9% | 21,950 | +7.3% | 0.00% | -33.3% |
| Q2 2023 | $337,016 | +162.8% | 20,450 | +46.1% | 0.00% | +200.0% |
| Q1 2023 | $128,240 | +14.4% | 14,000 | -10.5% | 0.00% | 0.0% |
| Q4 2022 | $112,054 | -100.0% | 15,650 | -83.3% | 0.00% | -66.7% |
| Q3 2022 | $235,235,000 | +317785.1% | 93,800 | +208.6% | 0.00% | +200.0% |
| Q2 2022 | $74,000 | -76.7% | 30,400 | -34.7% | 0.00% | -66.7% |
| Q1 2022 | $318,000 | +16.9% | 46,550 | +38.3% | 0.00% | 0.0% |
| Q4 2021 | $272,000 | +177.6% | 33,650 | +236.5% | 0.00% | +200.0% |
| Q3 2021 | $98,000 | +46.3% | 10,000 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $67,000 | -25.6% | 10,000 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $90,000 | +34.3% | 10,000 | -0.2% | 0.00% | 0.0% |
| Q4 2020 | $67,000 | -99.9% | 10,017 | +0.2% | 0.00% | 0.0% |
| Q3 2020 | $50,000,000 | – | 10,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 985,210 | $10,345,000 | 6.10% |
| Broadfin Capital, LLC | 3,568,122 | $37,465,000 | 5.54% |
| JW Asset Management, LLC | 444,439 | $4,667,000 | 3.42% |
| ARMISTICE CAPITAL, LLC | 1,688,000 | $17,724,000 | 2.09% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,655,494 | $38,383,000 | 1.73% |
| FALCON POINT CAPITAL, LLC | 661,490 | $6,284,000 | 0.91% |
| KNOTT DAVID M | 158,555 | $1,665,000 | 0.71% |
| Perceptive Advisors | 3,098,010 | $32,530,000 | 0.62% |
| Sio Capital Management, LLC | 91,413 | $960,000 | 0.50% |
| HEARTLAND ADVISORS INC | 700,000 | $7,350,000 | 0.48% |